Treatment of toenail onychomycosis with 2% butenafine and 5% Melaleuca alternifolia (tea tree) oil in cream

被引:61
作者
Syed, TA
Qureshi, ZA
Ali, SM
Ahmad, S
Ahmad, SA
机构
[1] Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA
[2] Punjab Univ, Lahore, Pakistan
[3] Shan Hosp, Karachi, Pakistan
[4] Komvux Coll, Boras, Sweden
[5] Windsor High Sch, Windsor, CA USA
关键词
onychomycosis; fungal infections; butenafine; tea tree oil; toenails; Melaleuca alternifolia; pharmaceutical creams;
D O I
10.1046/j.1365-3156.1999.00396.x
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
The prevalence of onychomycosis, a superficial fungal infection that destroys the entire nail unit, is rising, with no satisfactory cure. The objective of this randomized, double-blind, placebo-controlled study was to examine the clinical efficacy and tolerability of 2% butenafine hydrochloride and 5% Melaleuca alternifolia oil incorporated in a cream to manage toenail onychomycosis in a cohort. Sixty outpatients (39 M, 21 F) aged 18-80 years (mean 29.6) with 6-36 months duration of disease were randomized to two groups (40 and 20), active and placebo. After 16 weeks, 80% of patients using medicated cream were cured, as opposed to none in the placebo group. Four patients in the active treatment group experienced subjective mild inflammation without discontinuing treatment. During follow-up, no relapse occurred in cured patients and no improvement was seen in medication-resistant and placebo participants.
引用
收藏
页码:284 / 287
页数:4
相关论文
共 17 条
[1]   Adverse drug reactions of the new oral antifungal agents - terbinafine, fluconazole, and itraconazole [J].
Amichai, B ;
Grunwald, MH .
INTERNATIONAL JOURNAL OF DERMATOLOGY, 1998, 37 (06) :410-415
[2]  
Baran R. L., 1997, Cutaneous infection and therapy., P149
[3]   Overview of topical therapy for common superficial fungal infections and the role of new topical agents [J].
Brennan, B ;
Leyden, JJ .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1997, 36 (02) :S3-S8
[4]  
BUCK DS, 1994, J FAM PRACTICE, V38, P601
[5]  
CRISSEY JT, 1995, MANUAL MED MYCOLOGY, P19
[6]   Oral terbinafine in the treatment of toenail onychomycosis: North American multicenter trial [J].
Drake, LA ;
Shear, NH ;
Arlette, JP ;
Cloutier, R ;
Danby, FW ;
Elewski, BE ;
GarnisJones, S ;
Giroux, JM ;
Gratton, D ;
Gulliver, W ;
Hull, P ;
Jones, HE ;
Journet, M ;
Krol, AL ;
Leyden, JJ ;
Maddin, SC ;
Ross, JB ;
Savin, RC ;
Scher, RK ;
Sibbald, GR ;
Tawfik, NH ;
Zaias, N ;
Tolpin, M ;
Evans, S ;
Marsolais, C ;
Chin, T ;
Lin, TH ;
Maher, T ;
Birnbaum, JE .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1997, 37 (05) :740-745
[7]   Treatment of onychomycosis: A randomized, double-blind comparison study with topical bifonazole-urea ointment alone and in combination with short-duration oral griseofulvin [J].
FriedmanBirnbaum, R ;
Cohen, A ;
Shemer, A ;
Bitterman, O ;
Bergman, R ;
Stettendorf, S .
INTERNATIONAL JOURNAL OF DERMATOLOGY, 1997, 36 (01) :67-69
[8]  
FUKUSHIRO R, 1992, RECENT PROGRESS IN ANTIFUNGAL CHEMOTHERAPY, P147
[9]   Onychomycosis in children: Prevalence and treatment strategies [J].
Gupta, AK ;
Sibbald, RG ;
Lynde, CW ;
Hull, PR ;
Prussick, R ;
Shear, NH ;
DeDoncker, P ;
Daniel, CR ;
Elewski, BE .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1997, 36 (03) :395-402
[10]  
HANEKE E, 1990, ONYCHOMYCOSES, P1